LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Myelodysplastic Syndrome Diagnosed With Peripheral Blood Samples

By LabMedica International staff writers
Posted on 14 Nov 2022

Myelodysplastic syndromes (MDS) encompass a heterogeneous group of clonal bone marrow neoplasms, with a median age at diagnosis of 70 years. MDS are characterized by recurrent cytogenetic and molecular abnormalities, morphologic dysplasia for one or more hematopoietic cell lineage and ineffective hematopoiesis.

Cytomorphological evaluation of bone marrow is the reference standard for the diagnosis of MDS and may be complemented by information obtained from conventional cytogenetic, flow cytometry and molecular profiling analysis. Peripheral blood neutrophil myeloperoxidase expression quantified by flow cytometric analysis has the potential to rule out MDS without requiring invasive bone marrow aspiration.


Image: Gating strategy for quantifying peripheral blood neutrophil myeloperoxidase expression (Photo courtesy of Grenoble University Hospital)
Image: Gating strategy for quantifying peripheral blood neutrophil myeloperoxidase expression (Photo courtesy of Grenoble University Hospital)

A large team of hematopathologists at the Grenoble Alpes University Hospital (Grenoble, France) and their colleagues are evaluating a cross-sectional diagnostic accuracy study of two index tests by comparison with a reference standard in consecutive unselected adult patients conducted at a single university hospital. The team evaluated a hypothesis that a flow cytometry-based method involving a single-use tube containing lyophilized reagents will provide the accuracy needed to reject a diagnosis of MDS by analysis of peripheral blood neutrophil myeloperoxidase expression, in addition to other hypotheses.

The study examined an approach involving a product called Lyotube Stain 468 (BD Biosciences, San Jose, CA, USA), compared with an approach using a laboratory-developed liquid reagent-based test, in evaluating possible MDS. The Lyotube Stain 468 product includes dried reagents associated with five fluorochromes, while the laboratory-developed test uses liquid reagents associated with the same fluorochromes. With both approaches, an anti-myeloperoxidase antibody is applied to samples, and myeloperoxidase expression from peripheral blood neutrophils is measured. The team used a BD Biosciences three-laser, eight-color BD FACSCanto-II flow cytometer. The primary outcome is the reference diagnosis of MDS or CMML established by bone marrow examination by two independent experienced hematopathologists blinded to the index test results.

The investigators identified the strengths of this study to include the use of an adequate reference approach to MDS diagnosis, limited spectrum bias owing to enrollment of unselected consecutive patients, and a prespecified threshold for evaluation of diagnostic accuracy. Limitations of the study that they identified include the single-center nature of the study setting, in addition to conventional cytogenetic and molecular profiling approaches not being available to all patients in the study. The study was published in the November 2022 issue of the journal BMJ Open.

Related Links:
Grenoble Alpes University Hospital
BD Biosciences


New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
8-Channel Pipette
SAPPHIRE 20–300 µL

Latest Hematology News

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
14 Nov 2022  |   Hematology

Platelets Could Improve Early and Minimally Invasive Detection of Cancer
14 Nov 2022  |   Hematology

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
14 Nov 2022  |   Hematology